Esreboxetine

Esreboxetine
Clinical data

Routes of administration	Oral
ATC code	None
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name (2S)-2-[(S)-(2-ethoxyphenoxy)phenyl methyl]morpholine
CAS Number	98819-76-2^Y
PubChem CID	65856
IUPHAR/BPS	4808
ChemSpider	59268^N
UNII	L8S50ZY490
KEGG	D09340^Y
Chemical and physical data
Formula	C₁₉H₂₃NO₃
Molar mass	313.391 g/mol
3D model (Jmol)	Interactive image
SMILES CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3
InChI InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1^N Key:CBQGYUDMJHNJBX-OALUTQOASA-N^N
^NY (what is this?)

Esreboxetine is a selective norepinephrine reuptake inhibitor which was under development by Pfizer for the treatment of neuropathic pain and fibromyalgia but failed to show significant benefit over currently available medications and was discontinued. It is the (S,S)-(+)-enantiomer of reboxetine and is even more selective in comparison.

However, recently it has been shown that esreboxetine could be effective in fibromyalgia patients.